Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma

(2012) Peter J Hosein et al.   BMC CANCER

Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?

(2012) Katia T. Papalezova et al.   JOURNAL OF SURGICAL ONCOLOGY

Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease

(2011) K. A. Bickenbach et al.   ANNALS OF SURGICAL ONCOLOGY

Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic Cancer

(2011) Jayme B. Stokes et al.   ANNALS OF SURGICAL ONCOLOGY

Histologic tumor involvement of superior mesenteric vein/portal vein predicts poor prognosis in patients with stage II pancreatic adenocarcinoma treated with neoadjuvant chemoradiation

(2011) Jiansheng Wang et al.   CANCER

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement

(2009) Mark P. Callery et al.   ANNALS OF SURGICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Borderline Resectable Pancreatic Cancer: The Importance of This Emerging Stage of Disease

(2008) Matthew H.G. Katz et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS